• 1. An automatic determination of thoria in thoria-urania mixtures
  Analyst, 1966,91, 208-210
• 2. An approach for correlating the structural and electrical properties of Zr4+-modified SrBi4Ti4O15/SBT ceramic
  Priyambada Nayak,Tanmaya Badapanda,Anil Kumar Singh,Simanchalo Panigrahi RSC Adv., 2017,7, 16319-16331
• 3. An all-solid-state asymmetric device based on a polyaniline hydrogel for a high energy flexible supercapacitor?
  Hamid Heydari,Mohammad B. Gholivand New J. Chem., 2017,41, 237-244
• 4. An artificial photosynthesis system comprising a covalent triazine framework as an electron relay facilitator for photochemical carbon dioxide reduction?
  Siquan Zhang,Shengyao Wang,Liping Guo,Hao Chen,Bien Tan,Shangbin Jin J. Mater. Chem. C, 2020,8, 192-200
• 5. An integrated cathode and solid electrolyte via in situ polymerization with significantly reduced interface resistance?
  Jialiang Yuan,Ran Dong,Yuan Li,Yang Liu,Zhuo Zheng,Yuxia Liu,Yan Sun,Benhe Zhong,Zhenguo Wu,Xiaodong Guo Chem. Commun., 2021,57, 13004-13007

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Azoles Imidazoles Substituted imidazoles

Professional Introduction to Ethyl 2-Hydroxy-2-(1H-imidazol-2-yl)acetate (CAS No. 1520922-51-3)

Ethyl 2-hydroxy-2-(1H-imidazol-2-yl)acetate, with the CAS number 1520922-51-3, is a significant compound in the field of chemical and pharmaceutical research. This compound has garnered attention due to its unique structural properties and potential applications in drug development and biochemistry. The presence of both hydroxyl and imidazole functional groups makes it a versatile intermediate for synthesizing various pharmacologically active molecules.

The imidazole moiety in ethyl 2-hydroxy-2-(1H-imidazol-2-yl)acetate is particularly noteworthy, as imidazole derivatives are widely recognized for their role in medicinal chemistry. These derivatives have been extensively studied for their antimicrobial, antiviral, and anti-inflammatory properties. Recent advancements in the field have highlighted the importance of imidazole-based compounds in the development of targeted therapies for various diseases.

One of the most compelling aspects of ethyl 2-hydroxy-2-(1H-imidazol-2-yl)acetate is its potential as a building block for more complex molecules. Researchers have been exploring its utility in the synthesis of small-molecule inhibitors that can modulate enzyme activity. For instance, studies have shown that derivatives of this compound can interact with specific protein targets, potentially leading to the development of new treatments for neurological disorders and cancer.

The hydroxyl group in ethyl 2-hydroxy-2-(1H-imidazol-2-yl)acetate also contributes to its reactivity, making it a valuable candidate for further chemical modifications. The ability to introduce additional functional groups allows chemists to tailor the compound's properties for specific applications. This flexibility has been exploited in the design of novel drug candidates that exhibit enhanced bioavailability and reduced toxicity.

In recent years, there has been a surge in interest regarding the use of ethyl 2-hydroxy-2-(1H-imidazol-2-yl)acetate in preclinical studies. Researchers are leveraging its structural features to develop compounds that can selectively target pathological processes without affecting healthy cells. This approach aligns with the growing trend toward precision medicine, where treatments are tailored to individual patients based on their unique biological profiles.

The synthesis of ethyl 2-hydroxy-2-(1H-imidazol-2-yl)acetate involves multi-step organic reactions that require careful optimization to ensure high yield and purity. Advances in synthetic methodologies have enabled more efficient production processes, making it feasible to conduct large-scale studies and clinical trials. The availability of this compound in pure form has facilitated its use in high-throughput screening campaigns, accelerating the discovery of new therapeutic agents.

The pharmacological potential of ethyl 2-hydroxy-2-(1H-imidazol-2-yl)acetate has also been explored in combination therapies. By pairing this compound with other bioactive molecules, researchers aim to create synergistic effects that can overcome drug resistance and improve treatment outcomes. Such combinations are particularly relevant in the context of chronic diseases where long-term management is essential.

Future research directions for ethyl 2-hydroxy-2-(1H-imidazol-2-yl)acetate include investigating its role in cellular signaling pathways and its potential as an antioxidant agent. The imidazole ring, known for its ability to chelate metal ions, may offer protective effects against oxidative stress, which is implicated in various diseases. Additionally, studying its interactions with biological macromolecules could provide insights into its mechanism of action and inform the design of next-generation drugs.

In conclusion, ethyl 2-hydroxy-2-(1H-imidazol-2-yl)acetate (CAS No. 1520922-51-3) represents a promising compound with diverse applications in pharmaceutical research. Its unique structural features and reactivity make it an invaluable tool for developing new drugs and understanding disease mechanisms. As research continues to uncover its potential, this compound is poised to play a significant role in advancing medical science and improving patient care.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)